AbstractA novel series of 5‐sulfinyl(sulfonyl)‐4‐arylsulfonyl‐substituted 1,3‐oxazoles has been synthesized, characterized and subjected to NCI in vitro assessment. Cancer cell lines of all subpanels were most sensitive to 2‐[4‐[(4‐fluorophenyl)sulfonyl]‐2‐(2‐furyl)‐1,3‐oxazol‐5‐yl]sulfinyl}acetamide (3 l). Its antiproliferative and cytotoxic activity averaged over each subpanel was manifested in a very narrow range of concentrations (GI50: 1.64–1.86 μM, TGI: 3.16–3.81 μM and LC50: 5.53–7.27 μM), i. e. practically did not depend on the origin of the cancer cell line. The COMPARE matrix using TGI vector showed a high positive correlation of 3 l (r=0.88) with the intercalating agent aclarubicin, which inhibits topoisomerases. The absence in the database of standard agents that have a high correlation with the cytotoxicity of this compound suggests that it may have a unique mechanism of action. According to the results of the docking analysis, the most promising anticancer target for compound 3 l is DNA topoisomerase IIβ. The obtained results indicate the anticancer activity of 5‐sulfinyl(sulfonyl)‐4‐arylsulfonyl‐substituted 1,3‐oxazoles, which may be useful for the development of new anticancer drugs. 2‐[4‐[(4‐Fluorophenyl)sulfonyl]‐2‐(2‐furyl)‐1,3‐oxazol‐5‐yl]sulfinyl}acetamide (3 l), as the most active, can be recommended for further in‐depth studies.
摘要 合成了一系列新型的 5-亚磺酰基(磺酰基)-4-芳基磺酰基取代的 1,3-恶唑,对其进行了表征并进行了 NCI 体外评估。所有亚型癌症细胞系对 2-[4-[(4-氟苯基)磺酰基]-2-(2-呋喃基)-1,3-恶唑-5-基]亚磺酰基}乙酰胺(3 l)最为敏感。它的抗增殖和细胞毒性活性在每个子板上的平均浓度范围很窄(GI50:1.64-1.86 μM,TGI:3.16-3.81 μM,LC50:5.53-7.27 μM),即实际上与癌细胞系的来源无关。使用 TGI 向量的 COMPARE 矩阵显示,3 l(r=0.88)与抑制拓扑异构酶的夹层剂阿克拉比星高度正相关。数据库中没有与该化合物的细胞毒性高度相关的标准药剂,这表明该化合物可能具有独特的作用机制。根据对接分析的结果,化合物 3 l 最有希望的抗癌靶点是 DNA拓扑异构酶 IIβ。研究结果表明,5-亚磺酰基(磺酰基)-4-芳磺酰基取代的 1,3- 恶唑具有抗癌活性,可用于开发新的抗癌药物。其中,2-[4-[(4-氟苯基)磺酰基]-2-(2-呋喃基)-1,3-恶唑-5-基]亚磺酰基}乙酰胺(3 l)的活性最高,可建议进一步深入研究。